Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway
Michael Lahn(Eli Lilly (United States)), Stephan Herbertz(Eli Lilly (Germany)), J. Scott Sawyer(Eli Lilly (United States)), Anja J. Stauber(Eli Lilly (United States)), Ivelina Gueorguieva(Eli Lilly (United Kingdom)), Kyla Driscoll(Eli Lilly (United States)), Shawn T. Estrem(Eli Lilly (United States)), Ann Cleverly(Eli Lilly (United Kingdom)), Durisala Desaiah(Eli Lilly (United States)), Susan C. Guba(Eli Lilly (United States)), Karim A. Benhadji(Eli Lilly (United States)), Christopher A. Slapak(Eli Lilly (United States))
Cited by 544Open Access
Abstract
Keywords: TGF-β, TGF-βRI kinase inhibitor, ALK5, galunisertib, LY2157299, cancer, clinical trials
Related Papers
No related papers found
Powered by citation graph analysis